On Sept. 9, 2025, Emergent BioSolutions announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000^®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government.

Deliveries are expected to begin in September. This brings the total projected sales for ACAM2000^® vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000^® is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection.

ACAM2000^® is a single-dose vaccine administered percutaneously via a bifurcated needle that is dipped into the vaccine solution that is used to prick the skin several times in the upper arm with a droplet of the vaccine.

The vaccine was first approved by the U.S. Food and Drug Administration (FDA) in 2007 for active immunization for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection, and was FDA approved in August 2024 for immunization against mpox in individuals determined to be at high-risk for mpox. ACAM2000^® is also licensed for smallpox in Canada, Australia and Singapore and is currently stockpiled both in the U.S. and internationally.

ACAM2000^® is indicated for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox and mpox infection.